KRAS and non-small cell lung carcinoma: More common KRAS co-mutations may impact therapy as retrospective analyses and critical reviews have posited that NSCLC patients with KRAS-Serine/Threonine Kinase 11 (STK11) co-mutations are likely to exhibit primary resistance to ICI treatments [11].